• 

  Aducanumab Setback? FDA Advisory Committee Meeting Presents Unexpected Snag
• 

  FDA Moves Forward on Aducanumab
• 

  Alzheimer’s Drug Trials Have Had a 99% Failure Rate. The Good News: There Are Currently More Than 100 in the Pipeline
• 

  AAIC 2020: Some Vaccinations May Cut Alzheimer’s Risk by 40%
• 

  Phil’s Journal: Reflections on a Friend’s Passing
• 

  Biogen Seeks FDA Approval for Alzheimer’s Drug Aducanumab
• 

  Phil’s Journal: Trials and Tribulations, or, My Latest Experience in Biogen Research
• 

  Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
• 

  Phil’s Journal: How Caregivers Help People With Dementia Avoid Developing Delirium in the Hospital
• 

  Phil’s Journal: Pandemic Disrupts Alzheimer’s Clinical Trials. Including Mine
• 

  Phil’s Journal: My Good Friend Is the First to Receive Biogen’s Alzheimer’s Drug in New Trial
• 

  A ‘Medical Emergency’: Experts Project Alzheimer’s Cases Will Triple by 2050
• 

  Harnessing the Brain’s Immune Cells to Remove Amyloid Plaques in Alzheimer’s
• 

  People With Dementia Are at Higher Risk of Coronavirus: Here’s How to Prepare
• 

  Biogen Spends $350 Million to Develop Gene Therapies For Alzheimer’s, Parkinson’s

Previous234Next